Project Grant R01AI198596
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas at Dallas $434,625 on February 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate genetic mechanisms of minocycline resistance in Acinetobacter baumannii, a WHO and CDC priority pathogen for antibiotic resistance. The research employs machine learning and bacterial genetics to characterize how disruption of the RuvB DNA repair protein confers resistance to...
- The National Institute of Allergy and Infectious Diseases awarded The Rockefeller University $798,670 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bioinformatics-guided methods for discovering novel antibiotics from previously inaccessible microbial sources. The project couples direct nanopore metagenomic sequencing with synthetic bioinformatic natural products discovery methods to identify complete biosynthetic gene clusters from...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $687,817 to the University of Texas Health Science Center at Houston on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacterial cell envelope signal transduction mechanisms relevant to antibiotic resistance. The recipient will conduct research to elucidate how the regulator of capsule synthesis (RCS) stress response...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify conserved antiviral host factors that restrict arbovirus replication across insect and mammalian hosts. The award funds development of an arbovirus rescue assay that screens viral immune evasion proteins (IEPs) encoded by mammalian viruses for their ability to sensitize...
- The National Institute of Allergy and Infectious Diseases awarded $583,822 to the University of Texas at Arlington on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial pathogens evade thymineless death during anti-folate antibiotic treatment. The research uses Listeria monocytogenes as a model organism to characterize three evasion pathways: the role of cyclic di-AMP (c-di-AMP) and its interaction with the PII family protein PstA...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to develop tools for marginal zone-specific gene expression manipulation in B cells. The project investigates how mature B cell subsets—follicular, marginal zone, and B-1 cells—contribute to protective immune responses in infection and pathogenic responses...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $808,607 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize AI-designed antimicrobial peptides targeting ESKAPE pathogens. The project integrates artificial intelligence, machine learning, chemical approaches, and computational tools to develop peptide-based therapeutics against multidrug-resistant bacteria including...
- The National Institute of Allergy and Infectious Diseases awarded $596,318 to The University of Texas Southwestern Medical Center on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define virulence factor functions in Salmonella enterica using minimal pathogen genomes. The research characterizes how a small network of SPI-2 type III secretion system effector proteins coordinate membrane scission of the Salmonella-containing vacuole (SCV) and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $236,407 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural basis of ARMA-mediated resistance to aminoglycoside antibiotics targeting the bacterial ribosome. The research addresses how ARMA methyltransferases confer high-level resistance to aminoglycosides—a cornerstone class of ribosome-binding antibacterial drugs used...
The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $826,690 on August 20, 2026, for a Project Grant (R01AI198596) to advance antimicrobial resistance prediction through artificial intelligence and whole-genome sequencing. The recipient will develop rapid, comprehensive, and accurate antimicrobial resistance (AR) prediction methods by integrating Oxford Nanopore long-read sequencing and artificial intelligence. Work spans three aims: deriving comprehensive molecular features for AR prediction using Nanopore reads to create a supervised contrastive learning algorithm; developing protein structure-guided AR prediction models through a framework called Graph-BAR that uses in silico predicted 3D protein structures (such as AlphaFold) to assess functional impact of bacterial genetic variants and predict resistance even for unobserved mutations; and creating open-source software and cloud-based infrastructure to disseminate bioinformatics pipelines and AR prediction models to researchers. The project will analyze bacterial molecular features including single nucleotide polymorphisms, copy number variations, structural variations, and DNA methylation, converting genetic features into structure-based features for improved prediction accuracy on smaller datasets. Place of performance is Dallas, Texas. The period of performance runs through July 31, 2031. The award is made under the Allergy and Infectious Diseases Research program (CFDA 93.855), which funds biomedical research and research training in infectious diseases and related areas through public and private nonprofit institutions and individuals.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $826.7k | 8/19/26 |